Skip to main content

Advertisement

Table 3 Hazard ratios (HRs) and 95 % confidence intervals (CIs) for fractures and potential risk factors in the time-dependent model

From: Tamoxifen use reduces the risk of osteoporotic fractures in women with breast cancer in Asia: a nationwide population-based cohort study

Variable Crude HR (95 % CI) p-value Adjusted HR (95 % CI) p-value
Age, years 1.10 (1.10-1.11) <0.0001 1.09 (1.08-1.10) <0.0001
Monthly income, NTD       
<= 15000 4.85 (3.98-5.91) <0.0001 1.34 (1.08-1.66) 0.009
15001-20000 2.25 (1.86-2.71) <0.0001 1.51 (1.25-1.82) <0.0001
>20000 1.00 Ref.   1.00 Ref.  
Comorbidity (yes vs. no)       
Hypertension 4.48 (3.94-5.09) <0.0001 1.27 (1.09-1.48) 0.002
Hyperlipidemia 2.19 (1.92-2.50) <0.0001 0.83 (0.72-0.96) 0.01
Diabetes 3.65 (3.18-4.19) <0.0001 1.59 (1.37-1.85) <0.0001
PAD 2.74 (2.00-3.74) <0.0001 0.99 (0.72-1.36) 0.96
Stroke 5.40 (4.27-6.83) <0.0001 1.38 (1.08-1.76) 0.01
Osteoporosis 3.11 (2.70-3.58) <0.0001 1.38 (1.19-1.59) <0.0001
Aromatase inhibitor use before the end point 1.18 (1.00-1.40) 0.049 0.80 (0.68-0.95) 0.01
  1. Manually adjusted for tamoxifen use, age, monthly income, comorbidity and aromatase inhibitor use before the end point
  2. PAD, peripheral artery disease